<!DOCTYPE html>
<html >

<head>

  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <title>Summary of Conferences 2016</title>
  <meta name="description" content="Conferences mainly regarding clinical pharmacology, pharmacometrics and medicine will be summarized here.">
  <meta name="generator" content="bookdown 0.3.11 and GitBook 2.6.7">

  <meta property="og:title" content="Summary of Conferences 2016" />
  <meta property="og:type" content="book" />
  <meta property="og:url" content="http://shanmdphd.github.io/Conferences/" />
  <meta property="og:image" content="http://shanmdphd.github.io/Conferences/images/cover.png" />
  <meta property="og:description" content="Conferences mainly regarding clinical pharmacology, pharmacometrics and medicine will be summarized here." />
  <meta name="github-repo" content="shanmdphd/shanmdphd.github.io" />

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="Summary of Conferences 2016" />
  
  <meta name="twitter:description" content="Conferences mainly regarding clinical pharmacology, pharmacometrics and medicine will be summarized here." />
  <meta name="twitter:image" content="http://shanmdphd.github.io/Conferences/images/cover.png" />

<meta name="author" content="Sungpil Han, M.D./Ph.D.">


<meta name="date" content="2017-03-21">

  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta name="apple-mobile-web-app-status-bar-style" content="black">
  
  
<link rel="prev" href="MFDS.html">
<link rel="next" href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html">
<script src="libs/jquery/jquery.min.js"></script>
<link href="libs/gitbook/css/style.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-fontsettings.css" rel="stylesheet" />










<link rel="stylesheet" href="css/style.css" type="text/css" />
</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li><a href="./">Conferences</a></li>

<li class="divider"></li>
<li class="chapter" data-level="1" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i><b>1</b> Introduction</a></li>
<li class="chapter" data-level="2" data-path="section-2.html"><a href="section-2.html"><i class="fa fa-check"></i><b>2</b> 심장내과</a></li>
<li class="chapter" data-level="3" data-path="-3.html"><a href="-3.html"><i class="fa fa-check"></i><b>3</b> 심장내과 3부</a></li>
<li class="chapter" data-level="4" data-path="cancer-immunotherapy.html"><a href="cancer-immunotherapy.html"><i class="fa fa-check"></i><b>4</b> Cancer immunotherapy</a></li>
<li class="chapter" data-level="5" data-path="bioimaging-2016-04-29.html"><a href="bioimaging-2016-04-29.html"><i class="fa fa-check"></i><b>5</b> Bioimaging 2016-04-29</a></li>
<li class="chapter" data-level="6" data-path="-fda-.html"><a href="-fda-.html"><i class="fa fa-check"></i><b>6</b> 신약개발을 위한 FDA의 바이오이미징 표준화 프로그램 |</a><ul>
<li class="chapter" data-level="6.1" data-path="-fda-.html"><a href="-fda-.html#-center-for-bioimaging-of-new-drug-development-amc"><i class="fa fa-check"></i><b>6.1</b> 김정곤 Center for Bioimaging of New Drug Development AMC</a></li>
</ul></li>
<li class="chapter" data-level="7" data-path="kscpt.html"><a href="kscpt.html"><i class="fa fa-check"></i><b>7</b> 2016 KSCPT</a><ul>
<li class="chapter" data-level="7.1" data-path="kscpt.html"><a href="kscpt.html#first-session"><i class="fa fa-check"></i><b>7.1</b> First Session</a><ul>
<li class="chapter" data-level="7.1.1" data-path="kscpt.html"><a href="kscpt.html#precision-medicine-a-clinical-pharmacological-perspective"><i class="fa fa-check"></i><b>7.1.1</b> 13:20~14:00 Precision Medicine: A Clinical Pharmacological Perspective</a></li>
<li class="chapter" data-level="7.1.2" data-path="kscpt.html"><a href="kscpt.html#the-role-of-pharmacogenomics-in-drug-development-regulatory-review-and-clinical-practice"><i class="fa fa-check"></i><b>7.1.2</b> 14:00~14:30 The role of pharmacogenomics in drug development, regulatory review and clinical practice</a></li>
<li class="chapter" data-level="7.1.3" data-path="kscpt.html"><a href="kscpt.html#the-liver-gut-microbiota-axis-modulates-inter-individual-variability-in-xenobiotic-disposition-and-toxicology"><i class="fa fa-check"></i><b>7.1.3</b> 14:30~15:00 The Liver-Gut Microbiota Axis Modulates Inter-Individual Variability in Xenobiotic Disposition and Toxicology</a></li>
</ul></li>
<li class="chapter" data-level="7.2" data-path="kscpt.html"><a href="kscpt.html#second-session"><i class="fa fa-check"></i><b>7.2</b> Second Session</a><ul>
<li class="chapter" data-level="7.2.1" data-path="kscpt.html"><a href="kscpt.html#the-role-of-stem-cells-in-discovery-and-validation-of-pharmacogenomic-markers"><i class="fa fa-check"></i><b>7.2.1</b> 15:20~15:50 The role of stem cells in discovery and validation of pharmacogenomic markers</a></li>
<li class="chapter" data-level="7.2.2" data-path="kscpt.html"><a href="kscpt.html#pharmacogenomics-and-epigenomics"><i class="fa fa-check"></i><b>7.2.2</b> 15:50~16:20 Pharmacogenomics and Epigenomics</a></li>
<li class="chapter" data-level="7.2.3" data-path="kscpt.html"><a href="kscpt.html#emerging-roles-of-human-cyp1b1-in-cancer-growth-and-metastasis"><i class="fa fa-check"></i><b>7.2.3</b> 16:20~16:50 Emerging roles of human CYP1B1 in cancer growth and metastasis</a></li>
<li class="chapter" data-level="7.2.4" data-path="kscpt.html"><a href="kscpt.html#omics-for-precision-medicine-clinical-implementation-in-oncology"><i class="fa fa-check"></i><b>7.2.4</b> 16:50~17:20 omics for precision Medicine : Clinical Implementation in oncology</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="8" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html"><i class="fa fa-check"></i><b>8</b> “Translation and Convergence for Future Medicine”</a><ul>
<li class="chapter" data-level="8.1" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#plenary-session-ii--rd-"><i class="fa fa-check"></i><b>8.1</b> Plenary Session II “의료기술및 R&amp;D 변화의최신동향”</a><ul>
<li class="chapter" data-level="8.1.1" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#lecture-1--------"><i class="fa fa-check"></i><b>8.1.1</b> 13:30 ~ 14:15 Lecture 1 :의료분야에서의 빅데이터 :임상연구 및 진료를 위한 애널리틱스의 활용</a></li>
<li class="chapter" data-level="8.1.2" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#lecture-2----"><i class="fa fa-check"></i><b>8.1.2</b> 14:15 ~ 15:00 Lecture 2 :합성 항체에서 합성 단백질로</a></li>
</ul></li>
<li class="chapter" data-level="8.2" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#parallel-session-i--chairperson--"><i class="fa fa-check"></i><b>8.2</b> Parallel Session I “의료분야에서의빅데이터” Chairperson :김태원(서울아산병원임상의학연구소장) [대강당]</a><ul>
<li class="chapter" data-level="8.2.1" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#lecture-1------alexander-turchin-harvard-university-brigham-and-womens-hospital-usa"><i class="fa fa-check"></i><b>8.2.1</b> Lecture 1 :전자의무기록에 기반한 임상 빅데이터 연구 Alexander Turchin (Harvard University, Brigham and Women’s Hospital, USA)</a></li>
<li class="chapter" data-level="8.2.2" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#lecture-2----tom-lawry-microsoft-corp.-usa"><i class="fa fa-check"></i><b>8.2.2</b> Lecture 2 : 의료분야에서의 빅데이터 분석 Tom Lawry (Microsoft Corp., USA)</a></li>
<li class="chapter" data-level="8.2.3" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#lecture-3-------"><i class="fa fa-check"></i><b>8.2.3</b> Lecture 3 :생물기작 기반 암 오믹스 데이터 분석 기법</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="9" data-path="acrep.html"><a href="acrep.html"><i class="fa fa-check"></i><b>9</b> ACREP</a><ul>
<li class="chapter" data-level="9.1" data-path="acrep.html"><a href="acrep.html#observational-study"><i class="fa fa-check"></i><b>9.1</b> Observational Study</a><ul>
<li class="chapter" data-level="9.1.1" data-path="acrep.html"><a href="acrep.html#contents"><i class="fa fa-check"></i><b>9.1.1</b> Contents</a></li>
</ul></li>
<li class="chapter" data-level="9.2" data-path="acrep.html"><a href="acrep.html#observational-study-pitfall-----"><i class="fa fa-check"></i><b>9.2</b> Observational Study의 Pitfall 및 이를 극복하기 위한 방법</a><ul>
<li class="chapter" data-level="9.2.1" data-path="acrep.html"><a href="acrep.html#experimental-study-yes"><i class="fa fa-check"></i><b>9.2.1</b> Experimental study? Yes</a></li>
<li class="chapter" data-level="9.2.2" data-path="acrep.html"><a href="acrep.html#experimental-study-no"><i class="fa fa-check"></i><b>9.2.2</b> Experimental study? No</a></li>
<li class="chapter" data-level="9.2.3" data-path="acrep.html"><a href="acrep.html#contents-1"><i class="fa fa-check"></i><b>9.2.3</b> Contents</a></li>
<li class="chapter" data-level="9.2.4" data-path="acrep.html"><a href="acrep.html#conclusion"><i class="fa fa-check"></i><b>9.2.4</b> Conclusion</a></li>
</ul></li>
<li class="chapter" data-level="9.3" data-path="acrep.html"><a href="acrep.html#diagnostic-test-biomarker-study"><i class="fa fa-check"></i><b>9.3</b> Diagnostic test &amp; Biomarker Study</a><ul>
<li class="chapter" data-level="9.3.1" data-path="acrep.html"><a href="acrep.html#contents---diagnostic-test"><i class="fa fa-check"></i><b>9.3.1</b> Contents - Diagnostic test</a></li>
<li class="chapter" data-level="9.3.2" data-path="acrep.html"><a href="acrep.html#contents---biomarker"><i class="fa fa-check"></i><b>9.3.2</b> Contents - Biomarker</a></li>
</ul></li>
<li class="chapter" data-level="9.4" data-path="acrep.html"><a href="acrep.html#----"><i class="fa fa-check"></i><b>9.4</b> 2차 자료원을 이용한 역학 연구군</a></li>
<li class="chapter" data-level="9.5" data-path="acrep.html"><a href="acrep.html#----clinical-prediction-model-individual-riskoutcome-probability--"><i class="fa fa-check"></i><b>9.5</b> 대규모 이차 자료원을 이용한 clinical prediction model : individual risk/outcome probability 예측 분석법</a></li>
<li class="chapter" data-level="9.6" data-path="acrep.html"><a href="acrep.html#web-r.org"><i class="fa fa-check"></i><b>9.6</b> Web-r.org</a><ul>
<li class="chapter" data-level="9.6.1" data-path="acrep.html"><a href="acrep.html#contents-2"><i class="fa fa-check"></i><b>9.6.1</b> Contents</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="10" data-path="prism-2016.html"><a href="prism-2016.html"><i class="fa fa-check"></i><b>10</b> Prism 2016</a><ul>
<li class="chapter" data-level="10.1" data-path="prism-2016.html"><a href="prism-2016.html#morning-session"><i class="fa fa-check"></i><b>10.1</b> Morning Session</a><ul>
<li class="chapter" data-level="10.1.1" data-path="prism-2016.html"><a href="prism-2016.html#lim-covariate-model"><i class="fa fa-check"></i><b>10.1.1</b> Lim Covariate model</a></li>
<li class="chapter" data-level="10.1.2" data-path="prism-2016.html"><a href="prism-2016.html#fda---lee"><i class="fa fa-check"></i><b>10.1.2</b> FDA - Lee</a></li>
<li class="chapter" data-level="10.1.3" data-path="prism-2016.html"><a href="prism-2016.html#pfizer"><i class="fa fa-check"></i><b>10.1.3</b> Pfizer</a></li>
</ul></li>
<li class="chapter" data-level="10.2" data-path="prism-2016.html"><a href="prism-2016.html#afternoon-session"><i class="fa fa-check"></i><b>10.2</b> Afternoon Session</a><ul>
<li class="chapter" data-level="10.2.1" data-path="prism-2016.html"><a href="prism-2016.html#kim"><i class="fa fa-check"></i><b>10.2.1</b> Kim</a></li>
<li class="chapter" data-level="10.2.2" data-path="prism-2016.html"><a href="prism-2016.html#strategic-application-of-pm-in-global-drug-development-experience-from-hanmi"><i class="fa fa-check"></i><b>10.2.2</b> Strategic application of PM in global drug development: Experience from Hanmi</a></li>
<li class="chapter" data-level="10.2.3" data-path="prism-2016.html"><a href="prism-2016.html#mbdd"><i class="fa fa-check"></i><b>10.2.3</b> MBDD</a></li>
<li class="chapter" data-level="10.2.4" data-path="prism-2016.html"><a href="prism-2016.html#pharmacometric-information-in-drug-label"><i class="fa fa-check"></i><b>10.2.4</b> Pharmacometric information in drug label</a></li>
<li class="chapter" data-level="10.2.5" data-path="prism-2016.html"><a href="prism-2016.html#pharmacometrics-in-dose-optimization"><i class="fa fa-check"></i><b>10.2.5</b> Pharmacometrics in Dose Optimization</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="11" data-path="MFDS.html"><a href="MFDS.html"><i class="fa fa-check"></i><b>11</b> MFDS-Asan Joint Symposium on Rare Diseases 2016</a><ul>
<li class="chapter" data-level="11.1" data-path="MFDS.html"><a href="MFDS.html#session-1-rare-diseases-in-korea-status-research-experiences"><i class="fa fa-check"></i><b>11.1</b> Session 1 Rare diseases in Korea : Status &amp; Research experiences</a><ul>
<li class="chapter" data-level="11.1.1" data-path="MFDS.html"><a href="MFDS.html#national-support-for-rare-disease-current-status-and-future-prospects"><i class="fa fa-check"></i><b>11.1.1</b> National support for rare disease : Current status and future prospects</a></li>
<li class="chapter" data-level="11.1.2" data-path="MFDS.html"><a href="MFDS.html#translational-research-for-drug-development-historical-perspective"><i class="fa fa-check"></i><b>11.1.2</b> Translational research for drug development : Historical perspective</a></li>
</ul></li>
<li class="chapter" data-level="11.2" data-path="MFDS.html"><a href="MFDS.html#session-2-global-regulatory-experiences-in-orphan-drug-development"><i class="fa fa-check"></i><b>11.2</b> Session 2 Global regulatory experiences in orphan drug development</a><ul>
<li class="chapter" data-level="11.2.1" data-path="MFDS.html"><a href="MFDS.html#considerations-for-drug-development-for-rare-diseases-cases-of-inborn-errors-of-metabolism"><i class="fa fa-check"></i><b>11.2.1</b> Considerations for drug development for rare diseases : Cases of inborn errors of metabolism</a></li>
<li class="chapter" data-level="11.2.2" data-path="MFDS.html"><a href="MFDS.html#role-of-pharmacometrics-in-the-development-of-orphan-drugs"><i class="fa fa-check"></i><b>11.2.2</b> Role of pharmacometrics in the development of orphan drugs</a></li>
</ul></li>
<li class="chapter" data-level="11.3" data-path="MFDS.html"><a href="MFDS.html#session-3-lessons-and-learned-rd-for-rare-disease"><i class="fa fa-check"></i><b>11.3</b> Session 3 Lessons and learned : R&amp;D for rare disease</a><ul>
<li class="chapter" data-level="11.3.1" data-path="MFDS.html"><a href="MFDS.html#lessons-from-an-orphan-drug-development-i"><i class="fa fa-check"></i><b>11.3.1</b> Lessons from an orphan drug development (I)</a></li>
<li class="chapter" data-level="11.3.2" data-path="MFDS.html"><a href="MFDS.html#lessons-from-an-orphan-drug-development-ii"><i class="fa fa-check"></i><b>11.3.2</b> Lessons from an orphan drug development (II)</a></li>
<li class="chapter" data-level="11.3.3" data-path="MFDS.html"><a href="MFDS.html#case-studies-on-inflammatory-bowel-disease-asan-medical-center"><i class="fa fa-check"></i><b>11.3.3</b> Case studies on inflammatory bowel disease Asan Medical Center</a></li>
<li class="chapter" data-level="11.3.4" data-path="MFDS.html"><a href="MFDS.html#case-studies-on-drug-targets-in-rare-ultra-rare-genetic-disorders"><i class="fa fa-check"></i><b>11.3.4</b> Case studies on drug targets in rare &amp; ultra-rare genetic disorders</a></li>
</ul></li>
<li class="chapter" data-level="11.4" data-path="MFDS.html"><a href="MFDS.html#session-4-asan-initia-tives-for-rare-disease"><i class="fa fa-check"></i><b>11.4</b> Session 4 Asan initia tives for rare disease</a><ul>
<li class="chapter" data-level="11.4.1" data-path="MFDS.html"><a href="MFDS.html#leverage-big-data-to-better-understand-rare-disease-states-and-patient-needs-rare-disease-registry-research-experience"><i class="fa fa-check"></i><b>11.4.1</b> Leverage big data to better understand rare disease states and patient needs (rare disease registry &amp; research experience)</a></li>
<li class="chapter" data-level="11.4.2" data-path="MFDS.html"><a href="MFDS.html#align-commercial-and-development-team-to-forecast-success-through-prism"><i class="fa fa-check"></i><b>11.4.2</b> Align commercial and development team to forecast success through “PRISM”</a></li>
<li class="chapter" data-level="11.4.3" data-path="MFDS.html"><a href="MFDS.html#knowledge-and-perceptions-of-clinical-research-of-patients-suffering-from-rare-diseases"><i class="fa fa-check"></i><b>11.4.3</b> Knowledge and perceptions of clinical research of patients suffering from rare diseases</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="12" data-path="toxicology-2016.html"><a href="toxicology-2016.html"><i class="fa fa-check"></i><b>12</b> Toxicology 2016</a><ul>
<li class="chapter" data-level="12.1" data-path="toxicology-2016.html"><a href="toxicology-2016.html#key-links"><i class="fa fa-check"></i><b>12.1</b> Key links</a></li>
<li class="chapter" data-level="12.2" data-path="toxicology-2016.html"><a href="toxicology-2016.html#session-i-2016-08-22"><i class="fa fa-check"></i><b>12.2</b> Session I 2016-08-22</a><ul>
<li class="chapter" data-level="12.2.1" data-path="toxicology-2016.html"><a href="toxicology-2016.html#---"><i class="fa fa-check"></i><b>12.2.1</b> 독성학 개론 및 발현기전 !!!!</a></li>
<li class="chapter" data-level="12.2.2" data-path="toxicology-2016.html"><a href="toxicology-2016.html#section-12.2.2"><i class="fa fa-check"></i><b>12.2.2</b> 면역독성 !</a></li>
<li class="chapter" data-level="12.2.3" data-path="toxicology-2016.html"><a href="toxicology-2016.html#-"><i class="fa fa-check"></i><b>12.2.3</b> 독성시험과 통계 !!</a></li>
<li class="chapter" data-level="12.2.4" data-path="toxicology-2016.html"><a href="toxicology-2016.html#section-12.2.4"><i class="fa fa-check"></i><b>12.2.4</b> 독성병리 !!</a></li>
<li class="chapter" data-level="12.2.5" data-path="toxicology-2016.html"><a href="toxicology-2016.html#--"><i class="fa fa-check"></i><b>12.2.5</b> 비임상시험결과의 임상시험 연계 !!!!</a></li>
</ul></li>
<li class="chapter" data-level="12.3" data-path="toxicology-2016.html"><a href="toxicology-2016.html#session-ii-2016-08-23"><i class="fa fa-check"></i><b>12.3</b> Session II 2016-08-23</a><ul>
<li class="chapter" data-level="12.3.1" data-path="toxicology-2016.html"><a href="toxicology-2016.html#---"><i class="fa fa-check"></i><b>12.3.1</b> 오믹스 기반을 이용한 독성평가 !</a></li>
<li class="chapter" data-level="12.3.2" data-path="toxicology-2016.html"><a href="toxicology-2016.html#--"><i class="fa fa-check"></i><b>12.3.2</b> 독성동태 및 대사 !!!</a></li>
<li class="chapter" data-level="12.3.3" data-path="toxicology-2016.html"><a href="toxicology-2016.html#--"><i class="fa fa-check"></i><b>12.3.3</b> 유전독성 및 발암성 !!</a></li>
<li class="chapter" data-level="12.3.4" data-path="toxicology-2016.html"><a href="toxicology-2016.html#section-12.3.4"><i class="fa fa-check"></i><b>12.3.4</b> 신경독성 !</a></li>
<li class="chapter" data-level="12.3.5" data-path="toxicology-2016.html"><a href="toxicology-2016.html#--"><i class="fa fa-check"></i><b>12.3.5</b> 식품의 위해도 평가 !</a></li>
<li class="chapter" data-level="12.3.6" data-path="toxicology-2016.html"><a href="toxicology-2016.html#section-12.3.6"><i class="fa fa-check"></i><b>12.3.6</b> 생식발생독성 !</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="13" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><i class="fa fa-check"></i><b>13</b> 2016년 신약임상개발 전문가 과정 “Clinical Research Science Expert Course for Cutting-edge Drug Development”</a><ul>
<li class="chapter" data-level="13.1" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#drug-discovery-and-preclinical-candidate-selection"><i class="fa fa-check"></i><b>13.1</b> Drug discovery and preclinical candidate selection</a><ul>
<li class="chapter" data-level="13.1.1" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#-1st"><i class="fa fa-check"></i><b>13.1.1</b> 김재은 (1ST)</a></li>
</ul></li>
<li class="chapter" data-level="13.2" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#preclinical-development-and-ind-gono-go-decision-using-case-studies"><i class="fa fa-check"></i><b>13.2</b> Preclinical development and IND go/no-go decision (using case studies)</a></li>
<li class="chapter" data-level="13.3" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#global-drug-development-and-interaction-with-regulatory-agencies-fda-emea-using-case-studies"><i class="fa fa-check"></i><b>13.3</b> Global drug development and interaction with regulatory agencies (FDA, EMEA) (using case studies)</a></li>
<li class="chapter" data-level="13.4" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#clinical-pharmacology"><i class="fa fa-check"></i><b>13.4</b> Clinical Pharmacology</a></li>
<li class="chapter" data-level="13.5" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#the-actual-development-and-operation-of-pharmacovigillance-system-in-korean-pharmaceutical-companies"><i class="fa fa-check"></i><b>13.5</b> The actual development and operation of Pharmacovigillance system in Korean pharmaceutical companies</a><ul>
<li class="chapter" data-level="13.5.1" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#experience-of-sop-development-pv-training-sharing-pv-audit-finding"><i class="fa fa-check"></i><b>13.5.1</b> Experience of SOP development &amp; PV training/ Sharing PV audit finding</a></li>
<li class="chapter" data-level="13.5.2" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#establishment-and-application-of-safety-database-system"><i class="fa fa-check"></i><b>13.5.2</b> Establishment and Application of Safety Database System:</a></li>
</ul></li>
<li class="chapter" data-level="13.6" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#open-innovation-in-drug-development"><i class="fa fa-check"></i><b>13.6</b> Open innovation in drug development</a></li>
<li class="chapter" data-level="13.7" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#clinical-development-strategy-and-plan-workshop"><i class="fa fa-check"></i><b>13.7</b> Clinical development strategy and plan workshop</a><ul>
<li class="chapter" data-level="13.7.1" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#course-intro---understanding-tpp-and-hcv"><i class="fa fa-check"></i><b>13.7.1</b> Course intro - Understanding TPP and HCV</a></li>
<li class="chapter" data-level="13.7.2" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#candidate-selection-through-poc"><i class="fa fa-check"></i><b>13.7.2</b> Candidate selection through PoC</a></li>
<li class="chapter" data-level="13.7.3" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#late-phase-development-commercialization"><i class="fa fa-check"></i><b>13.7.3</b> Late phase Development &amp; Commercialization</a></li>
<li class="chapter" data-level="13.7.4" data-path="acrep.html"><a href="acrep.html#----"><i class="fa fa-check"></i><b>13.7.4</b> 국내 사례 소개 및 질의/응답</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="14" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html"><i class="fa fa-check"></i><b>14</b> The 2nd A3 Pharmacometrics Symposium</a><ul>
<li class="chapter" data-level="14.1" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#young-scientist-session"><i class="fa fa-check"></i><b>14.1</b> Young Scientist Session</a><ul>
<li class="chapter" data-level="14.1.1" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#modeling-of-mycoplasma-tuberculosis-biomarkders-for-cure"><i class="fa fa-check"></i><b>14.1.1</b> Modeling of mycoplasma tuberculosis biomarkders for cure</a></li>
<li class="chapter" data-level="14.1.2" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#integrative-pkpd-modling-and-simulation-of-amenamevir-for-treatment-of-recurrent-genital-herpes"><i class="fa fa-check"></i><b>14.1.2</b> Integrative PKPD modling and simulation of Amenamevir for treatment of recurrent genital herpes</a></li>
<li class="chapter" data-level="14.1.3" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#model-based-meta-analysis-to-quantify-and-compare-the-efficacy-of-non-hormonal-drugs-on-menopausal-hot-flashes"><i class="fa fa-check"></i><b>14.1.3</b> Model Based Meta-Analysis to quantify and compare the efficacy of non-hormonal drugs on menopausal Hot flashes</a></li>
<li class="chapter" data-level="14.1.4" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#dosing-optimization-in-obesity-using-pharmacometrics-approach-population-pk-and-pd-of-meropenem-in-non-obese-obese-and-mobidly-obese-patients"><i class="fa fa-check"></i><b>14.1.4</b> Dosing optimization in obesity using pharmacometrics approach: population PK and PD of meropenem in non-obese, obese and mobidly obese patients</a></li>
</ul></li>
<li class="chapter" data-level="14.2" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#application-session"><i class="fa fa-check"></i><b>14.2</b> Application Session</a><ul>
<li class="chapter" data-level="14.2.1" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#the-application-of-pharmacometrics-in-individual-therapy-in-china"><i class="fa fa-check"></i><b>14.2.1</b> The application of pharmacometrics in individual therapy in China</a></li>
<li class="chapter" data-level="14.2.2" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#pd-model-fo-bayesian-prediction-of-myelosuppression-rpofiles-based-on-routine-clinical-data-after-gemcitabine-and-carboplatin-treatment"><i class="fa fa-check"></i><b>14.2.2</b> PD model fo Bayesian Prediction of myelosuppression rpofiles based on routine clinical data after gemcitabine and carboplatin treatment</a></li>
<li class="chapter" data-level="14.2.3" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#modeling-and-validating-chronic-pharmacological-manupulation-of-circadian-rhythms"><i class="fa fa-check"></i><b>14.2.3</b> Modeling and validating chronic pharmacological manupulation of circadian rhythms</a></li>
<li class="chapter" data-level="14.2.4" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#application-of-pkpd-modeling-and-simulation-in-antiviral-drug-development"><i class="fa fa-check"></i><b>14.2.4</b> Application of PK/PD modeling and simulation in antiviral drug development</a></li>
<li class="chapter" data-level="14.2.5" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#pharmacometrics-in-clinical-practice-pop-pk-analysis-of-febuxostat-in-patients-with-severe-renal-impairment"><i class="fa fa-check"></i><b>14.2.5</b> pharmacometrics in clinical practice: pop PK analysis of febuxostat in patients with severe renal impairment</a></li>
</ul></li>
<li class="chapter" data-level="14.3" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#regulation"><i class="fa fa-check"></i><b>14.3</b> Regulation</a><ul>
<li class="chapter" data-level="14.3.1" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#the-new-japanese-guideline-on-population-pk-and-pd-analysis"><i class="fa fa-check"></i><b>14.3.1</b> The new Japanese guideline on population PK and PD analysis</a></li>
<li class="chapter" data-level="14.3.2" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#how-to-increase-the-number-of-population-pk-analysis-reports-submitted-to-mfds-in-korea"><i class="fa fa-check"></i><b>14.3.2</b> How to increase the number of population PK analysis reports submitted to MFDS in Korea</a></li>
<li class="chapter" data-level="14.3.3" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#ema-regulations-on-meling-issues"><i class="fa fa-check"></i><b>14.3.3</b> EMA regulations on meling issues</a></li>
<li class="chapter" data-level="14.3.4" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#recent-examples-of-impact-of-pharmacometrics-in-decision-making"><i class="fa fa-check"></i><b>14.3.4</b> Recent examples of impact of pharmacometrics in decision making</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="15" data-path="asrm-2016.html"><a href="asrm-2016.html"><i class="fa fa-check"></i><b>15</b> ASRM 2016</a><ul>
<li class="chapter" data-level="15.1" data-path="asrm-2016.html"><a href="asrm-2016.html#plenary-lectures"><i class="fa fa-check"></i><b>15.1</b> Plenary lectures</a><ul>
<li class="chapter" data-level="15.1.1" data-path="asrm-2016.html"><a href="asrm-2016.html#plenary-2"><i class="fa fa-check"></i><b>15.1.1</b> Plenary 2</a></li>
<li class="chapter" data-level="15.1.2" data-path="asrm-2016.html"><a href="asrm-2016.html#plenary-lecture-3-the-importance-of-long-acting-reversible-contraception-larc"><i class="fa fa-check"></i><b>15.1.2</b> Plenary Lecture 3 : The importance of Long-acting reversible contraception (LARC)</a></li>
<li class="chapter" data-level="15.1.3" data-path="asrm-2016.html"><a href="asrm-2016.html#plenary-4"><i class="fa fa-check"></i><b>15.1.3</b> Plenary 4</a></li>
<li class="chapter" data-level="15.1.4" data-path="asrm-2016.html"><a href="asrm-2016.html#plenary-5"><i class="fa fa-check"></i><b>15.1.4</b> Plenary 5</a></li>
<li class="chapter" data-level="15.1.5" data-path="asrm-2016.html"><a href="asrm-2016.html#plenary-6-update-on-congenital-adrenal-hyperplasia"><i class="fa fa-check"></i><b>15.1.5</b> Plenary 6 Update on Congenital Adrenal Hyperplasia</a></li>
<li class="chapter" data-level="15.1.6" data-path="asrm-2016.html"><a href="asrm-2016.html#plenary-7---why-parents-matter-epigenetically-genomic-imprinting-in-health-and-disease"><i class="fa fa-check"></i><b>15.1.6</b> Plenary 7 - Why Parents Matter (Epigenetically): Genomic Imprinting in Health and Disease</a></li>
<li class="chapter" data-level="15.1.7" data-path="asrm-2016.html"><a href="asrm-2016.html#plenary-8-aua-bruce-stewart-memorial-lecture-the-futures-of-malereproductive-medicine"><i class="fa fa-check"></i><b>15.1.7</b> Plenary 8: AUA Bruce Stewart Memorial Lecture: The Futures of (Male(Reproductive)) Medicine</a></li>
</ul></li>
<li class="chapter" data-level="15.2" data-path="asrm-2016.html"><a href="asrm-2016.html#prize-oral"><i class="fa fa-check"></i><b>15.2</b> Prize Oral</a><ul>
<li class="chapter" data-level="15.2.1" data-path="asrm-2016.html"><a href="asrm-2016.html#mtor-inhibitors-preserve-fertility-in-a-murine-model-a-novel-pharmacologic-approach-to-fertility-preservation-during-gonadotoxic-chemotherapy"><i class="fa fa-check"></i><b>15.2.1</b> mTOR inhibitors preserve fertility in a murine model : a novel pharmacologic approach to fertility preservation during gonadotoxic chemotherapy</a></li>
<li class="chapter" data-level="15.2.2" data-path="asrm-2016.html"><a href="asrm-2016.html#verification-of-accuracy-safety-for-ovarian-reserve-assessment-with-optical-coherence-tomography-using-mouse-ovary"><i class="fa fa-check"></i><b>15.2.2</b> Verification of accuracy &amp; safety for ovarian reserve assessment with optical coherence tomography using mouse ovary</a></li>
<li class="chapter" data-level="15.2.3" data-path="asrm-2016.html"><a href="asrm-2016.html#o-6-randomized-controlled-trial-of-low-5-vs.-ultralow-2-oxygen-tension-for-in-vitro-development-of-human-embryos"><i class="fa fa-check"></i><b>15.2.3</b> O-6 RANDOMIZED CONTROLLED TRIAL OF LOW (5%) VS. ULTRALOW (2%) OXYGEN TENSION FOR IN VITRO DEVELOPMENT OF HUMAN EMBRYOS</a></li>
</ul></li>
<li class="chapter" data-level="15.3" data-path="asrm-2016.html"><a href="asrm-2016.html#symposium-overview-of-food-and-drug-administration-fda-regulations-of-products-used-to-treat-reproductive-conditions-in-women"><i class="fa fa-check"></i><b>15.3</b> Symposium : Overview of Food and Drug Administration (FDA) Regulations of Products Used to Treat Reproductive Conditions in Women</a><ul>
<li class="chapter" data-level="15.3.1" data-path="asrm-2016.html"><a href="asrm-2016.html#richard-d.-mcfarland-m.d.-ph.d."><i class="fa fa-check"></i><b>15.3.1</b> Richard D. McFarland, M.D., Ph.D.</a></li>
<li class="chapter" data-level="15.3.2" data-path="asrm-2016.html"><a href="asrm-2016.html#rhonda---cder-drug-review-process"><i class="fa fa-check"></i><b>15.3.2</b> Rhonda - CDER Drug review process</a></li>
<li class="chapter" data-level="15.3.3" data-path="asrm-2016.html"><a href="asrm-2016.html#cdrh-center-for-devices-and-radiological-health"><i class="fa fa-check"></i><b>15.3.3</b> CDRH (Center for Devices and Radiological Health)</a></li>
<li class="chapter" data-level="15.3.4" data-path="asrm-2016.html"><a href="asrm-2016.html#endometriosis-tuesday-expo-theater"><i class="fa fa-check"></i><b>15.3.4</b> Endometriosis, Tuesday EXPO theater</a></li>
</ul></li>
<li class="chapter" data-level="15.4" data-path="asrm-2016.html"><a href="asrm-2016.html#scientific-congress-prize-paper-session-2"><i class="fa fa-check"></i><b>15.4</b> Scientific Congress Prize Paper Session 2</a><ul>
<li class="chapter" data-level="15.4.1" data-path="asrm-2016.html"><a href="asrm-2016.html#o-91-preovulatory-protein-restriction-ppr-disrupted-amino-acid-aa-kinetics-and-mitochondrial-structure-and-function-in-the-rat-oocyte"><i class="fa fa-check"></i><b>15.4.1</b> O-91 PREOVULATORY PROTEIN RESTRICTION (PPR): DISRUPTED AMINO ACID (AA) KINETICS AND MITOCHONDRIAL STRUCTURE AND FUNCTION IN THE RAT OOCYTE</a></li>
<li class="chapter" data-level="15.4.2" data-path="asrm-2016.html"><a href="asrm-2016.html#o-92-effects-of-resveratrol-on-polycystic-ovary-syndrome"><i class="fa fa-check"></i><b>15.4.2</b> O-92 EFFECTS OF RESVERATROL ON POLYCYSTIC OVARY SYNDROME</a></li>
<li class="chapter" data-level="15.4.3" data-path="asrm-2016.html"><a href="asrm-2016.html#o-93-genome-wide-dna-methylation-changes-in-mouse-zygotes-associated-with-superovulation"><i class="fa fa-check"></i><b>15.4.3</b> O-93 GENOME-WIDE DNA METHYLATION CHANGES IN MOUSE ZYGOTES ASSOCIATED WITH SUPEROVULATION</a></li>
<li class="chapter" data-level="15.4.4" data-path="asrm-2016.html"><a href="asrm-2016.html#o-94-can-we-expect-to-improve-age-at-menopause-predictions-with-repeated-amh-measurements"><i class="fa fa-check"></i><b>15.4.4</b> O-94 CAN WE EXPECT TO IMPROVE AGE AT MENOPAUSE PREDICTIONS WITH REPEATED AMH MEASUREMENTS?</a></li>
</ul></li>
<li class="chapter" data-level="15.5" data-path="asrm-2016.html"><a href="asrm-2016.html#oral-presentation"><i class="fa fa-check"></i><b>15.5</b> Oral Presentation</a><ul>
<li class="chapter" data-level="15.5.1" data-path="asrm-2016.html"><a href="asrm-2016.html#o-229-the-impact-of-elagolix-on-quality-of-life-in-women-with-endometriosis-associated-pain-results-from-two-randomized-placebo-controlled-studies-using-the-endometriosis-health-profile-questionnaire-hugh-taylor"><i class="fa fa-check"></i><b>15.5.1</b> O-229 THE IMPACT OF ELAGOLIX ON QUALITY OF LIFE IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN: RESULTS FROM TWO RANDOMIZED, PLACEBO-CONTROLLED STUDIES USING THE ENDOMETRIOSIS HEALTH PROFILE QUESTIONNAIRE (Hugh Taylor)</a></li>
<li class="chapter" data-level="15.5.2" data-path="asrm-2016.html"><a href="asrm-2016.html#o-230-direct-and-indirect-costs-associated-with-endometriosis-related-surgery-among-employed-women-in-the-us"><i class="fa fa-check"></i><b>15.5.2</b> O-230 DIRECT AND INDIRECT COSTS ASSOCIATED WITH ENDOMETRIOSIS-RELATED SURGERY AMONG EMPLOYED WOMEN IN THE US</a></li>
<li class="chapter" data-level="15.5.3" data-path="asrm-2016.html"><a href="asrm-2016.html#o-231-new-procedure-for-the-endometriosis-diagnosis"><i class="fa fa-check"></i><b>15.5.3</b> O-231 NEW PROCEDURE FOR THE ENDOMETRIOSIS DIAGNOSIS</a></li>
<li class="chapter" data-level="15.5.4" data-path="asrm-2016.html"><a href="asrm-2016.html#o-232-elagolix-on-endometrium"><i class="fa fa-check"></i><b>15.5.4</b> O-232 Elagolix on endometrium</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="16" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html"><i class="fa fa-check"></i><b>16</b> KSCPT 2016 Fall</a><ul>
<li class="chapter" data-level="16.1" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#therapeutics-new-target"><i class="fa fa-check"></i><b>16.1</b> Therapeutics : New target</a><ul>
<li class="chapter" data-level="16.1.1" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#a-new-target-for-hiv-1-aids-drug"><i class="fa fa-check"></i><b>16.1.1</b> A new target for HIV-1 / AIDS drug</a></li>
<li class="chapter" data-level="16.1.2" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#new-drug-target-for-osteoporosis-gpr120"><i class="fa fa-check"></i><b>16.1.2</b> New drug target for osteoporosis: GPR120</a></li>
<li class="chapter" data-level="16.1.3" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#strategy-for-anti-cancer-target"><i class="fa fa-check"></i><b>16.1.3</b> Strategy for Anti-Cancer Target</a></li>
<li class="chapter" data-level="16.1.4" data-path="toxicology-2016.html"><a href="toxicology-2016.html#--"><i class="fa fa-check"></i><b>16.1.4</b> 재발자궁경부암 항암화학방사선 온열동시치료</a></li>
</ul></li>
<li class="chapter" data-level="16.2" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#drug-development-i"><i class="fa fa-check"></i><b>16.2</b> Drug development I</a><ul>
<li class="chapter" data-level="16.2.1" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#non-clinical-considerations-for-fih"><i class="fa fa-check"></i><b>16.2.1</b> Non-clinical considerations for FIH</a></li>
<li class="chapter" data-level="16.2.2" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#------"><i class="fa fa-check"></i><b>16.2.2</b> 임상약리학 주도 환자 대상 초기임상시험의 경험과 전망</a></li>
<li class="chapter" data-level="16.2.3" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#the-contribution-of-clinical-pharmacologist-in-global-drug-development-real-examples-from-a-big-pharma"><i class="fa fa-check"></i><b>16.2.3</b> The Contribution of Clinical Pharmacologist in Global Drug Development: Real Examples from a Big Pharma</a></li>
</ul></li>
<li class="chapter" data-level="16.3" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#drug-development-ii--"><i class="fa fa-check"></i><b>16.3</b> Drug development II 신상구 (차바이오컴플렉스)</a><ul>
<li class="chapter" data-level="16.3.1" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#babe------vs-"><i class="fa fa-check"></i><b>16.3.1</b> BA/BE 임상시험 결과분석 시 고려사항: 분산투여 vs 추가시험</a></li>
<li class="chapter" data-level="16.3.2" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#the-use-of-pharmacometrics-for-drug-development-in-korea"><i class="fa fa-check"></i><b>16.3.2</b> The use of pharmacometrics for drug development in Korea</a></li>
<li class="chapter" data-level="16.3.3" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#fatal-bia-10-2474-phase-i-clinical-trial-what-can-we-learn"><i class="fa fa-check"></i><b>16.3.3</b> Fatal BIA 10-2474 Phase I Clinical Trial : What Can We Learn?</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="17" data-path="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><a href="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><i class="fa fa-check"></i><b>17</b> 2016-11-18 Will big data and data science reshape the horizon of drug development?, If so, how?</a><ul>
<li class="chapter" data-level="17.1" data-path="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><a href="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html#jscpt"><i class="fa fa-check"></i><b>17.1</b> JSCPT</a><ul>
<li class="chapter" data-level="17.1.1" data-path="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><a href="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html#--------"><i class="fa fa-check"></i><b>17.1.1</b> 대규모 약물 유도 전사체 정보 기반 항암 신약 재창출</a></li>
<li class="chapter" data-level="17.1.2" data-path="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><a href="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html#big-data-platform-for-multi-national-data-collaboration"><i class="fa fa-check"></i><b>17.1.2</b> Big data platform for multi-national data collaboration</a></li>
<li class="chapter" data-level="17.1.3" data-path="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><a href="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html#yoshinori-ochiai-pharmaceuticals-and-medical-devices-agency"><i class="fa fa-check"></i><b>17.1.3</b> Yoshinori Ochiai (Pharmaceuticals and Medical Devices Agency)</a></li>
<li class="chapter" data-level="17.1.4" data-path="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><a href="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html#how-big-data-national-registry-data-can-be-a-game-changer"><i class="fa fa-check"></i><b>17.1.4</b> How big data (national registry data) can be a game changer?</a></li>
</ul></li>
<li class="chapter" data-level="17.2" data-path="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><a href="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html#how-can-clinical-pharmacology-facilitate-collaboration-between-the-drug-development-industry-and-academia-particularly-in-the-asian-pacific-region"><i class="fa fa-check"></i><b>17.2</b> How can clinical pharmacology facilitate collaboration between the drug development industry and academia, particularly in the Asian-Pacific region?</a><ul>
<li class="chapter" data-level="17.2.1" data-path="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><a href="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html#thyroid"><i class="fa fa-check"></i><b>17.2.1</b> Thyroid</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="18" data-path="section.html"><a href="section.html"><i class="fa fa-check"></i><b>18</b> 2017-03-20</a></li>
<li class="chapter" data-level="19" data-path="reference.html"><a href="reference.html"><i class="fa fa-check"></i><b>19</b> Reference</a></li>
<li class="divider"></li>
<li><a href="http://shanmdphd.github.io">Back to shanmdphd.github.io</a></li>

</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">Summary of Conferences 2016</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="toxicology-2016" class="section level1">
<h1><span class="header-section-number">Chapter 12</span> Toxicology 2016</h1>
<ul>
<li>author: 한성필</li>
<li>date: 2016-08-22 ~ 2016-08-23</li>
<li>venue: 숙명여자대학교 백주년기념관 2층 컨벤션 센터</li>
</ul>
<div id="key-links" class="section level2">
<h2><span class="header-section-number">12.1</span> Key links</h2>
<ul>
<li><a href="http://www.toxmut.or.kr/">한국독성학회</a></li>
<li><a href="https://www.toxicology.org/about/history/docs/poster_Benchmark.pdf">Benchmarks in Toxicology</a><br />
</li>
<li><a href="http://www.ich.org/products/guidelines.html">ICH guideline</a></li>
<li><a href="http://drug.mfds.go.kr/Data/KO_NO/r88w76h15j1a68p96o45d64s58h22o81p54b66q55j14u82.pdf">의약품의 임상시험 수행과 품목허가를 위한 비임상시험가이드라인</a></li>
<li><a href="www.nifds.go.kr/nifds/08_part/part02_c_b.jsp?mode=view&amp;article_no=7483&amp;pager.offset=0&amp;board_no=167">생물의약품 비임상시험 가이드라인(2014)</a></li>
</ul>
</div>
<div id="session-i-2016-08-22" class="section level2">
<h2><span class="header-section-number">12.2</span> Session I 2016-08-22</h2>
<div id="---" class="section level3 tabset">
<h3><span class="header-section-number">12.2.1</span> 독성학 개론 및 발현기전 !!!!</h3>
<ul>
<li>홍진태: 충북대학교</li>
<li>독성학에 많은 분야가 있다. (규제독성학 : 가습기살균제)</li>
<li>Toxin vs Toxicant man-made</li>
<li>Toxicity, Hazard(상태), Safety(risk의 반대 개념), Risk(probability), Risk Assessment</li>
<li>Idiosyncratic reaction, delayed toxicity(중국에서 온 조류, 잔류성 농약 먹고 우리나라 와서 독성)</li>
<li>화학적 상호작용 - Additive, synergistic, potentiation, antagonism</li>
<li><strong>용량-반응관계</strong> - 유해성 평가에서 중요한 factor - Dose-response - sigmoid하게 나타난다. 그룹별로 나타난걸 Quantal이라고 한다.
<ul>
<li>직선형으로 표현할 수도 있다.</li>
<li>기울기도 봐야 한다. B는 다루기가 힘든 약 (Steep) LD50는 같을 지라도 주의해야 한다.</li>
</ul></li>
<li>효력Potency vs 효능efficacy
<ul>
<li>Morphine / aspirin</li>
</ul></li>
<li>Therapeutic index - LD<sub>50</sub>/ED<sub>50</sub></li>
<li>Margin of safety - LD<sub>1</sub>/ED<sub>99</sub><br />
</li>
<li>Margin of exposure = exposure level / TD<sub>10</sub></li>
<li>Subchronic / chronic dose response - Liver necrosis - LOAEL NOAEL(No observed AE level)
<ul>
<li>ADI, RfD, TDI 만성 노출에 대한 허용치를 결정하는 전형적인 시발점</li>
<li>Benchmark dose (모델링을 사용해서 결정)<br />
</li>
</ul></li>
<li>threshold</li>
<li>독성 영향 인자
<ul>
<li>selective</li>
<li>생체내 전환<br />
</li>
<li>malathion : 사람 vs 곤충(곤충에만 축적)</li>
<li>빈도, 농도, 용량, 부위, 경로, 시각(chronopharmacology)-마우스 KCN치사율에 대한 circadian susceptibility(심박동 낮고 안정화된 아침에 투약)</li>
<li>내인성 인자: 종, 성별, 연령, 체중/신체구성</li>
</ul></li>
<li>동물 독성 연구 - 동물에서의 노출과 영향을 연구
<ul>
<li>TCDD에 노출된 rat의 종양 발생<br />
</li>
</ul></li>
<li>독성 시험의 유형 - 단회, 반복 투여 독성 시험, 유전 독성, 면역 독성, 발암성 시험, 국소 독성 시험, 메커니즘 연구, OMICS 활용 독성</li>
<li>Mechanism of Toxicity
<ul>
<li>Delivery, Reaction, Toxicity, Repair</li>
</ul></li>
<li>Exposure of Toxic chemicals -&gt; Ultimate toxicant + Target molecule</li>
<li>Type of Ultimate toxicants and their sources
<ul>
<li>대사체가 xenobiotic toxicant</li>
<li>Reactive oxygen or nitrogen species as ultimate toxicants</li>
<li><strong>Endogenous compounds as ultimate toxicants (lipid - peroxidation, Bilirubin)</strong><br />
</li>
</ul></li>
<li>Distribution (Specialized transport - ochratoxi, MPTP into DA neuron</li>
<li>Accumulation (Away from the target - MDR)<br />
</li>
<li>Excretion vs reabsorption
<ul>
<li>Excretion (volatile, non-volatile)</li>
<li>reabsorption (tubular fluid reabsorption, carrier in kidney, intestinal lumen) - 우리 몸에선 약산, 약알칼리, 중성의 약물 - PH가 중요하다. PKA
<ul>
<li>salicylic acid (알칼리에서 reabs 감소), morphine(산성에서 reabs 감소)</li>
</ul></li>
</ul></li>
<li>Toxication vs detoxication
<ul>
<li>electrophiles : nonionic, cationic</li>
<li>nucleophiles : amygdalin -&gt; cyanide</li>
<li>free radical formation
<ul>
<li>Xenobiotics -&gt; super oxide</li>
<li>P450 reductase PQ, DR, NF 전자를 하나 받아서 reduct한 효소로 바뀐게 산소와 반응해서 free radical 만들게 된다. reduce된다. (전자빠지면서) reactant가 된다.</li>
<li>Endogenous sources of O2<br />
</li>
<li>One electron oxidation by peroxidases or P450</li>
<li>superoxide anion radical toxication</li>
</ul></li>
<li>Detoxication of free radical
<ul>
<li>SOD, Catalase, GPX, HO(ineffective), ONOO- : free radical scavenge</li>
</ul></li>
</ul></li>
<li>Reaction (반응 - ultimate toxicants-target)
<ul>
<li>Target molecule(DNA, ptn, memb lipid, coenzyme)</li>
<li>Types of reactions
<ul>
<li>Non-covalent : hydrogen, memb receptor, PKC, acridine</li>
<li>Covalent</li>
</ul></li>
<li>hydrogen abstract :
<ul>
<li>R-SH -&gt; RS*</li>
<li>CH3 -&gt; CH2*, DNA -&gt; C4 radical, lipid - lipid peroxidation</li>
</ul></li>
<li>effects of toicants on targets
<ul>
<li>dysfunction of target (mimicking endogenous ligands, morphine(opiate receptor), protein function impairment<br />
</li>
<li>destruction of targets<br />
</li>
<li>cellular dysfunction</li>
<li>TK, GPCR, Hormone receptor<br />
</li>
<li>excitable cell dysfunction - alternation of signal</li>
<li>cocaine (adrenergic vasoconstriction)</li>
</ul></li>
</ul></li>
<li>Toxic alternation
<ul>
<li>Mechanism of apoptosis + ATP depletion, Ca increase, overpopulation of ROS(PARP increase - DNA injury))<br />
</li>
<li>Protein repair(ubi, autophagy)</li>
</ul></li>
</ul>
</div>
<div id="section-12.2.2" class="section level3">
<h3><span class="header-section-number">12.2.2</span> 면역독성 !</h3>
<ul>
<li>최경철: 충북대학교</li>
<li>Introduction to WBC</li>
<li>Introduction to lymphoid organs<br />
</li>
<li>Sentinal cells - MQ, DC, Mast cells</li>
<li>Structure of LN - B cell은 cortex에 존재함. Ag 만나 proliferation -&gt; class switching (항체를 만든다, cortex에서)</li>
<li>Structure of spleen - Red pulp (RBC), white pulp(WBC)</li>
<li>Hypersensitivity reactions (과민반응) - I, II, III(혈관염), IV</li>
<li>Quiz:
<ol style="list-style-type: decimal">
<li>Acquired immunity - B cells</li>
<li>BCR -&gt; antibody</li>
<li>Helper T -&gt; CD4</li>
<li>major 2차면역기관 - A,E</li>
</ol></li>
<li>ICH.org - E2B, CTD, MedDra</li>
<li>ICH S6 guideline - TDAR, phenotyping 등을 해야 한다.<br />
</li>
<li>S8 guideline (immunotoxicology studies) - STS (standard toxicology study) -&gt; factors to consider in the eval of potential immunotoxicity</li>
<li>Hapten (low MW, unpredictable, immunogenecity)</li>
<li>Introduction to antibody</li>
<li>Type II, III - no standard, non-clinical test (Coombs test)</li>
<li>murine LLNA (local LN assay) - thymidine -&gt; DNA 합성시 incorporation - beta counter로 잴 수 있다.</li>
<li>Quiz:
<ol style="list-style-type: decimal">
<li>면역독성 카테고리 포함 안되는것? - Abnormal APC (IS, IG, HS, AI)</li>
<li>면역조직 아닌거? - Thyroid gl.</li>
<li>Type IV 과민증 (Buehler , maximization, optimization) 아닌것은?</li>
<li>Passive cutaneous anaphyl, maxi test - 동물은? guinea pig</li>
<li>Autoimmunity 비이상적인 현상</li>
<li>ImmunoSuppression 아닌 것은? myelosupp, 면역 기관 위축, serum globulin증가(wrong!), 감염증가</li>
</ol></li>
</ul>
</div>
<div id="-" class="section level3">
<h3><span class="header-section-number">12.2.3</span> 독성시험과 통계 !!</h3>
<ul>
<li>이영주: 경희대학교</li>
<li>기술통계, 추측통계</li>
<li>대표값 + 산포도</li>
<li>산술평균 - 극단치에 영향을 많이 받음, 명목변수, 순위변수에는 부적합(예-암1기, 2기), skewed distribution에는 부적합</li>
<li>기하평균 - 분포가 한쪽으로 치우쳐 로그변환하여 사용하는 경우(Cmax), 곱셈으로 계산하는 값의 평균 (AUC)</li>
<li>대부분의 경우는 SD가 옳다. 산포성 SD. 통계처리시 SE. 추측통계시.
<ul>
<li>triplicate를 세번이상 하는 경우는 SE써도 된다.</li>
</ul></li>
<li>추측통계
<ul>
<li>모수 - 모집단을 대표.</li>
<li>신뢰구간 point estimate 99%CI -&gt; 더 넓어진다. (90% CI에 비해)</li>
</ul></li>
<li>통계적 가설검증 (귀무가설을 기각)</li>
<li>검정통계량 - 가설의 옳고 그름을 판단. - 계산.<br />
</li>
<li>t<sub>alpha/2</sub> = 3.182 이상이면 H0(귀무가설) 기각영역</li>
<li>Decision Tree</li>
<li>서열척도(ordinal scale) - 비모수적 Spearman, MW U test, Kruskal-Wallis</li>
</ul>
</div>
<div id="section-12.2.4" class="section level3">
<h3><span class="header-section-number">12.2.4</span> 독성병리 !!</h3>
<ul>
<li>김용범: 안전성평가연구소</li>
<li>같은 동물인데도 병리가 다를 수 있다. (정상이 다를 수 있어.)</li>
<li>시험물질 관련 조직변화를 표로 작성하여 소견의 중요성을 판단</li>
<li>periportal vacuolation. Artifact. inadequate artifact.</li>
<li>부검 : 가장 중요함.</li>
<li>gross 소견 기술: 출혈보다 discoloration. 표준화 통일화</li>
<li>장기중량 측정.</li>
<li>표준화된 방식으로 삭정( 잘라야 함. ) 같은 조직은 일관성 있게.</li>
<li>독성병리학자. 표준화된 표로 정리할 수 있는 능력.</li>
<li>대조군의 중요성 강조. 수컷 대조군- 수컷 고용량 - 저용량 순서로 한다.</li>
<li>현미경 진단.
<ul>
<li>STP. ESTP. BSTP. JSTP. 표준화를 위한 기관들.</li>
<li>위치. - necrosis, neuron, hippocampus, brain</li>
<li>분포 - 국소, 다소성, 미만성.</li>
<li>병변 등급 - 주관적일 수 있다</li>
<li>Apoptosis- 세포막 손상 없다. necrosis - 광범위 세포막 손상 -&gt; 염증</li>
<li>병적과정 - 혈행 장애.</li>
<li>치유 및 수복 - 재생, 반흔(섬유화)</li>
<li>적응 기전 : 위축, 비대, 과형성, 화생.</li>
<li>종양: 세포조절 안됨.</li>
</ul></li>
<li>Peer review</li>
<li>아급성 혹은 만성 설치류 독성 시험. 암수 대저군 1마리(25%) 임의 5마리 고농도(10%) : 모든 슬라이드 동료 검토</li>
<li>Pathology working group. PWG. 병리전문가 패널. - 검토는 어떻게 수행? 각자의 의견을 투표. 의견이 틀릴때는 조율. 최종적으로 다수에 의해.</li>
</ul>
</div>
<div id="--" class="section level3">
<h3><span class="header-section-number">12.2.5</span> 비임상시험결과의 임상시험 연계 !!!!</h3>
<ul>
<li>반복투여가 중요함. (NOAEL) - 대조군 대비 부작용이 유의하게 증가하지 않는 최고용량. 생물학적 유의성이 중요. (통계적 유의성이 없더라도)</li>
<li>FDA pregnancy categories, IARC Carcinogens classification (group 1, 2, 3, 4)</li>
<li>반복투여 독성 시험 NOAEL을 잘 잡잡기 위해 4번의 기회가 있다.</li>
<li>단기(4주)~ pivotal.</li>
<li>단기에서 독성을 잘 봐야함. 충분히 높은 용량으로 시작한 뒤에 낮춰가는 쪽으로 해야 함. 그 반대는 참 힘들것.</li>
<li>Safety margin = NOAEL에서의 exposure / MRHD에서의 exposure
<ul>
<li>exposure가 중요하다.<br />
</li>
</ul></li>
<li>비임상시험의 적용
<ul>
<li>누구를 대상으로? 최초 투여 용량은 어떻게 결정하는가? 용량 얼마씩 증량</li>
<li>이런 질문이 비임상시험에서 나오게 된다.</li>
</ul></li>
<li>Phase 1a (FIH) 임상시험대상자 (환자 vs 건강인?)
<ul>
<li>비임상시험 결과 -&gt; Seriousness? measurable? -&gt; if no, 환자관련 의약품. If yes, 건강한 시험대상자</li>
</ul></li>
<li>Clinical starting dose 설정법</li>
<li>NOAEL/PAD based approach - estimating the maximum safe starting dose in initial clinical trials (2005-07)
<ul>
<li>초기 임상개시 가능 최고 용량 (MRSD)
<ol style="list-style-type: decimal">
<li>각 동물 종의 NOAEL결정</li>
<li>HED 계산</li>
<li>가장 적당한 동물종 선정</li>
<li>safety factor 적용</li>
<li>MRSD의 산정</li>
<li>PAD고려하여 선정.</li>
</ol></li>
</ul></li>
<li>Human equivalent dose (HED) calculation
<ul>
<li>사람 용량으로 외삽하는 가장 적합한 방법을 사용하여 HED 산출. (체표면적에 따라서) mg/kg을 mg/m2으로 변경해 준다.</li>
<li>km mouse 3 rat 6 monkey 12 dog 20 human 37</li>
<li>h:Donkey:Monkey(rabbit):Rat:mouse = 1:2:3:6:12(mg/kg) = 동일 mg/m2</li>
<li>mouse 120mg/kg * 3/37 = human 10mg/kg, rat 60mg/kg = human 10mg/kg</li>
</ul></li>
<li>Most appropriate species selection
<ul>
<li>적당한 종을 사용해라. 잘 모를때는 더 민감한 동물 써라. HED가 더 낮은 동물을 선택하면 된다.<br />
</li>
</ul></li>
<li>safety factor application - 좀 낮춰서 투약하자.
<ul>
<li>Default safety factor = 10</li>
</ul></li>
<li>MRSD 산정(Maximum recommended starting dose)</li>
<li>Quiz : rat 4주 반복 독성 시험에서의 NOAEL 60mg/kg. Rat는 appropriate, safety factor = 10.
<ul>
<li>60mg/kg rat km = 6, human 36, 나누면 1mg/kg이 된다. 60kg라고 보면 60mg으로 하면 된다.</li>
<li>HED = 60mg/kg * 6/37 = human 10mg/kg</li>
<li>MRSD = HED / SF = 10/10 = 1mg/kg = 60mg<br />
</li>
</ul></li>
<li>PAD (Pharmacologically active dose, PAD) 고려.
<ul>
<li>PAD = 3mg/kg일때 임상 초회 용량 30으로 할 수 있다.</li>
</ul></li>
<li>MABEL Guideline
<ul>
<li>TGN1412 (CD28-Super Mab)</li>
<li>HED 16 mg/kg , safety factor 160<br />
</li>
<li>원숭이 NOAEL = 50mg/kg (BSA based HED = 16mg/kg)</li>
<li>원숭이 PAD = 2.5 - 25 mg/kg 원숭이 PAD-HED = 0.8 ~ 8 mg/kg , starting dose = 0.1mg/kg</li>
<li>사고 이후의 주장들 1. 5ug/kg 2. 3ug/kg으로 해야한다. 3. receptor occupancy - antagonist는 90% receptor occupancy가 적합. agonist는 10% receptor occupancy면 충분함. 이를 위해서는 1ug/kg면 충분함.</li>
<li>MABEL 아마도 사람에게서 약효가 나타날 용량. Minimal anticipated biological effect level)</li>
<li>2007-06 새로운 가이드라인 제정됨.<br />
</li>
<li>animal in vitro -&gt; allometric equation 산출 - animal in vivo</li>
<li>human in vitro -&gt; 적용 . human MABEL 산출</li>
</ul></li>
<li>PK-guided approach - dose대신 전신 노출(systemic exposure) 이용하여 동물 결과를 외삽(extrapolation)
<ul>
<li>SD ( starting dose) = AUC * CL<sub>h</sub></li>
<li>NOAEL 비글에서 AUC 20ug*hr/mL 예상되는 제거율은 CL<sub>h</sub> = 15L/hr 효력의 차이는 0.1 EC50/EC50</li>
</ul></li>
<li>건강인 아닌 악성 종양 환자에서의 starting dose
<ul>
<li>항암제에서.. 주료.</li>
<li>ICH S9
<ul>
<li>57개의 임상시험을 다 분석했다. 여기서 나온 공식으로 계산.</li>
</ul></li>
</ul></li>
<li>임상-비임상 밀접한 관련.
<ul>
<li>개별 임상시험의 특성</li>
</ul></li>
<li>NOAEL/PAD based approach</li>
<li>MRSD = NOAEL * (km<sub>animal</sub>/km<sub>human</sub>)/SF</li>
</ul>
</div>
</div>
<div id="session-ii-2016-08-23" class="section level2">
<h2><span class="header-section-number">12.3</span> Session II 2016-08-23</h2>
<div id="---" class="section level3">
<h3><span class="header-section-number">12.3.1</span> 오믹스 기반을 이용한 독성평가 !</h3>
<ul>
<li>최진희 서울시립대학교</li>
<li>systems toxicology - science+engineering+computing <strong>Multi-omics technology</strong></li>
<li>biological model 만들어.</li>
<li>in silico - combination - 더 넓은 독성 개념을 얻을 수 있어</li>
<li>개발의 platform으로 사용할 수 있음.</li>
<li>Exposure -&gt; molecular -&gt; cellular -&gt; organ responses -&gt; organism responses -&gt; population responses</li>
<li>Integration is the key.<br />
</li>
<li>New regulation (i.e. REACH), TOX21, TOX CAST</li>
<li>adverse outcome pathway</li>
<li><a href="https://www.toxicology.org/about/history/docs/poster_Benchmark.pdf">Benchmarks in Toxicology</a></li>
</ul>
</div>
<div id="--" class="section level3">
<h3><span class="header-section-number">12.3.2</span> 독성동태 및 대사 !!!</h3>
<ul>
<li>speaker: 신소영(원광대 약학대학)</li>
<li>Efficacy 의약품의 효능 - 약물활성(Activity, A), 감수성(Sensitivity, S), 약물농도(Concentration, C)</li>
<li>약물의 조직에서 농도대신 약물농도에 혈중 약물 농도 변화로 효능을 기술가능. (가정)</li>
<li>ADME</li>
<li>toxicokinetics - 정의 : 약효를 기대하지 않는 농약이나 일반 화학물질의 체내 동태
<ul>
<li>ICH 가이드라인</li>
<li>독성시험기준 정의 : 독성시험 수행시 시험물질의 전신노출도 평가하기 위해 약물동태학적 자료를 산출하는 시험.</li>
</ul></li>
<li>Model
<ul>
<li>가장 간단한 모델만 사용할 것임<br />
</li>
<li>대부분의 약물은 one compartment model로 설명이 됨.</li>
<li>Compartment model, PBPK model</li>
<li>zero- and first-order elimination</li>
</ul></li>
<li>CL
<ul>
<li>rate of elimination / concentration = dX/dt / C<sub>p</sub> - 약물이 혈중에서 소실되는 속도를 혈중 약물 농도로 나누어준 값 =</li>
<li>CL is dose divided by AUC</li>
</ul></li>
<li>F
<ul>
<li>약물 또는 그 활성대사체가 제제로부터 전신 순환혈로 흡수되는 속도와 양의 비율</li>
<li>IV는 F=1</li>
</ul></li>
<li>비선형성
<ul>
<li>흡수 riboflavin(transporter GI 포화)</li>
<li>높은 농도에서는 모든 효소가 포화되어 0차반응에 가까워짐</li>
<li>낮은 혈중 농도에서는 1차반응에 가까워짐.</li>
</ul></li>
<li>Michaelis-Menten
<ul>
<li>소실속도 = -dC/dt = V<sub>max</sub>C/K<sub>m</sub>+C<br />
</li>
<li>약물농도가 Km보다 훨씬 클때 -dC/dt = Vmax</li>
<li>훨씬 작을때 -dC/dt = Vmax*C/Km</li>
<li>선형동태구간/비선형동태구간</li>
</ul></li>
</ul>
</div>
<div id="--" class="section level3">
<h3><span class="header-section-number">12.3.3</span> 유전독성 및 발암성 !!</h3>
<ul>
<li>speaker: 김지영(안전성평가연구소) <a href="mailto:fnkim@kitox.re.kr">fnkim@kitox.re.kr</a></li>
<li>3 primary test battery (OECD)
<ul>
<li>화장품에 대한 독성자료 (유럽)는 안받고 있다. 화장품, 유럽은 염색체 빼고 해야함.</li>
</ul></li>
<li>ICH</li>
<li>Aim of genetic toxicology testing
<ul>
<li>Genotoxicigy, mutagenicity</li>
</ul></li>
<li>Forward mutation(braoder mutagen identification)</li>
<li>Backward mutation(reversion) - more restricted and accurate</li>
<li>TG490
<ul>
<li>in vitro genetic toxicology test</li>
<li>mouse lymphoma assay</li>
<li>TK6 assay로 불리기도 한다.</li>
</ul></li>
<li>Chromosomal abberation
<ul>
<li>수적 이상</li>
<li>구조적 이상</li>
<li>pre-S : chromosome abberration vs post-S : chromatid abberation</li>
</ul></li>
<li>In vivo genetic toxicology tests
<ul>
<li>Tests for primary DNA damage(3 battery에는 안들어가.)
<ul>
<li>Fast, single-strand breaks(SSB) and/or alkali-labile sites(ALS)</li>
<li>Liver and stomach were used. (가장 중요한 장기)</li>
</ul></li>
</ul></li>
<li>Sens and spec
<ul>
<li>MN, CA, MLA는 specificity가 낮다. (S9 처리해서 phase I은 많이 하지만 phase II(detoxification)를 구현할 수 있는 in vitro시험은 없기 때문에 specificity 낮음)</li>
</ul></li>
<li>발암성 시험
<ul>
<li>detection of potential to induce neoplastic lesions</li>
<li>요구되지 않는 경우 - 악성종양치료제, 3년 이내 생존</li>
</ul></li>
<li>“예전거로 해주세요.”
<ul>
<li>개정된 시험이 더 고비용이기 때문에 요청하는 경우가 많다.</li>
<li>그러나 그렇게 하면 안된다.</li>
</ul></li>
</ul>
</div>
<div id="section-12.3.4" class="section level3">
<h3><span class="header-section-number">12.3.4</span> 신경독성 !</h3>
<ul>
<li>위명복: 강원대학교</li>
<li>산화적 손상에 대한 신경계 취약성
<ul>
<li>항산화방어기전 중등도 낮음(catalase, GPx, vit-E)</li>
<li>tight junction 단백감소, MMP 간접활성</li>
<li>microglia에 의한 ROS 및 cytokine 생산.</li>
</ul></li>
<li>신경손상 형태
<ul>
<li>neuronopathy -&gt; gliosis (methyl mercury, Tins, MPTP(heroin))</li>
<li>myelionopathy</li>
</ul></li>
<li>TG: 설치류 신경독성평가, 발달 신경독성평가</li>
<li>Neurotoxicity screening battery
<ul>
<li>Tier 1 - FOB, locomotor, GFAP ELISA, histopathology</li>
<li>Tier 2</li>
</ul></li>
<li>비동물대체법(non-animal alternative methods)
<ul>
<li>세포를 가지고 하는 것이다.</li>
<li>대체한계성 - 모든 것을 대체할 수 없다.</li>
</ul></li>
<li>Stroke, parkinson, SCI, etc..</li>
<li>CNS injury marker - BBB(Evan’s), microglia(OX-42), etc..</li>
</ul>
</div>
<div id="--" class="section level3">
<h3><span class="header-section-number">12.3.5</span> 식품의 위해도 평가 !</h3>
<ul>
<li>최시내 케이앤에이컨설팅</li>
<li>체내로 유입되는 양이 중요함</li>
<li>급성 섭취 노출량 예측
<ul>
<li>잔류량이 composite 분석 결과에 해당.</li>
</ul></li>
<li>노출 평가</li>
<li>용량-반응 관계 규명
<ul>
<li>extrapolation : high-dose -&gt; low-dose</li>
<li>기본 원칙 : threshold approach, non-threshold approach</li>
<li>Non threshold -&gt; extrapolation
<ul>
<li>cancer potency = Q1star = upper bound</li>
</ul></li>
<li>Threshold approach - NOAEL
<ul>
<li>NOAEL을 활용한 RfD의 유도</li>
<li>NOAEL or LOAEL / UF x MF ; UF = uncertainty factor</li>
</ul></li>
</ul></li>
<li>Risk characterization
<ul>
<li>Threshold
<ul>
<li>Hazard quotient = [exposure level] / [reference dose]</li>
<li>exposure와 reference dose는 동일한 노출 기간에 근거</li>
</ul></li>
</ul></li>
</ul>
</div>
<div id="section-12.3.6" class="section level3">
<h3><span class="header-section-number">12.3.6</span> 생식발생독성 !</h3>
<ul>
<li>김종춘: 전남대학교</li>
<li>segment I, II, III (KFDA, ICH)
<ol style="list-style-type: decimal">
<li>Fertility and early embryonic development study</li>
<li>Embryo-fetal development study</li>
<li>Peri- and postnatal development study</li>
</ol></li>
<li>Segment I
<ul>
<li>Stage I ~ XIV - 56일 걸린다.</li>
<li>같은 stage끼리 비교해야 함.</li>
</ul></li>
<li>Segment II
<ul>
<li>기형변이</li>
<li>teratogenesis</li>
<li>600kda 이하의 분자량이어야 태반 통과.</li>
<li>연골 + 경골의 염색<br />
</li>
</ul></li>
<li>Segment III
<ul>
<li>한배새끼관찰, F1 성장, 행동, 생식기능시험</li>
</ul></li>
<li>Key point
<ul>
<li>생식발생 위해성 급증</li>
<li>시험법</li>
<li>실험동물 종과 계통 선택</li>
<li>결과의 해석</li>
<li>종류와 특성 및 작용 기전</li>
<li>3Rs principle</li>
</ul></li>
</ul>

</div>
</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="MFDS.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook/js/app.min.js"></script>
<script src="libs/gitbook/js/lunr.js"></script>
<script src="libs/gitbook/js/plugin-search.js"></script>
<script src="libs/gitbook/js/plugin-sharing.js"></script>
<script src="libs/gitbook/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook/js/plugin-bookdown.js"></script>
<script src="libs/gitbook/js/jquery.highlight.js"></script>
<script>
require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": true,
"twitter": true,
"google": false,
"weibo": false,
"instapper": false,
"vk": false,
"all": ["facebook", "google", "twitter", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": "https://github.com/shanmdphd/shanmdphd.github.io/edit/master/_ConferencesSource/2016-08-22-toxicology.Rmd",
"text": "Edit"
},
"download": ["bookdown.pdf", "bookdown.epub", "bookdown.mobi"],
"toc": {
"collapse": "subsection"
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    if (location.protocol !== "file:" && /^https?:/.test(script.src))
      script.src  = script.src.replace(/^https?:/, '');
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
